Welcome, subscribers!
We’re back with another edition of Elevator Pitches.
If you enjoy our newsletter, please consider sharing with a friend or colleague who might also appreciate our work.
In this week’s issue, we're happy to share four new ideas.
This week, we're unveiling investments that span from revolutionizing healthcare management to redefining luxury on tropical shores. Dive into the future with cutting-edge technology innovations that are setting new standards in their fields, alongside a banking institution that's reshaping financial landscapes.
Keep reading to learn more.
Disclaimer: Nothing here constitutes professional and/or financial advice. You alone assume any risk with the use of any information contained herein. We may own positions in the securities listed. Please do your own due diligence.
To the investment managers who read this, you can send us your letters at elevatorpitches@substack.com or on Twitter (and Threads!) if you’d like to be included in a future issue.
Let’s get to it.
Voss Capital revealed a new long, R1 RCM Inc (RCM), which handles revenue cycle management for health care providers. The company is heavily shorted, but Voss thinks the negative sentiment is misplaced and a new management team (who came over in a recent acquisition) can right the ship. In addition to their quarterly letter (shown below), Voss also went into great detail on this position in a recent note.
New core sized long: R1 (RCM)
R1 is a top player in outsourced Revenue Cycle Management for large hospitals and physician groups. Outsourced revenue cycle management is still in the early innings with only about 30% penetration, and we believe R1 has the most complete and scalable independent (i.e., not affiliated with an insurance company) solution in the marketplace, in what could prove to be a “winner take most” industry. With hospital profitability under pressure and coding and regulatory complexity ever increasing, R1 offers substantial savings via regional labor arbitrage and automation technology to customers through more efficient revenue collection.
The current management team came from Cloudmed, which R1 acquired very recently in June of 2022, and has undertaken the challenging task of cultural and technological integration while being relative public market newcomers under immense scrutiny. Cloudmed offers modular or single-point RCM solutions as opposed to a full end-to-end offering, and it counts 95 out of the top 100 hospitals in the US as customers. Cloudmed is a solid business with upwards of 40% EBITDA margins and 117% net revenue retention, and we think they can achieve a mid-teens revenue CAGR over the next few years while opening the door to upselling R1’s more robust service offering across the broader customer base.
We believe with Cloudmed’s technological focus and vast access to data (they touch over $900 billion of Net Patient Revenue across all hospital EMRs), a bit of a network effect is likely to take hold, as R1’s army of engineers (most of their $100 million+ in capex is directed towards software development) are utilizing Machine Learning and, yes, AI, to automate processes to drive further efficiency of economics to be shared with customers. The company recently announced a collaboration with Microsoft to improve billing coding productivity. We believe there is a significant opportunity to both expand margins and expand their technological leadership. The CEO has a technology-oriented background and has been very consistent and outspoken since becoming CEO about the long-term margin enhancing opportunities that Machine Learning and AI could generate for the company.
R1 currently has terrible negative sentiment as evidenced by a massive multiple de-rating and 18% short interest. It is getting hit by both stylistic (floating debt, healthcare IT, SMID) and idiosyncratic factors (accounting concerns, customer loss/bankruptcy, negative estimate revisions). While we cannot dismiss all these negatives as “nothing,” it is our variant view that under the covers things at the company are much better than they appear at first glance and most of the bearish arguments miss the forest for the trees.
The level of risk of an investment is in part a function of the valuation paid relative to many outcomes. Waiting for perfect near-term clarity on a situation like RCM would be costly and could negate any chance at outsized alpha. Where we have had big winners is not where we prioritize near-term clarity, but rather precise downside valuation protection under a variety of normal economic outcomes. R1 certainly fits the bill here, with investors overly focused on guidance for the next three months while we are focused on getting comfortable with the cash flow dynamics three years out. We believe there is limited downside over the next few years as there is still latent profitability building that will show up from maturing customers and ongoing Modular (Cloudmed) growth.
Twelve months from now, we think the investment narrative will have transformed significantly as management signs new customers without “paying to play”, earnings quality improves substantially, deleveraging begins in earnest, and hospitals become incrementally healthier, leading to what will be viewed as a scarce, high quality healthcare IT asset that could be trading closer to fair value which we peg at 15x 2026 FCF, ~100% higher over the next two years. Although this is certainly an execution story, these numbers do not require much new business to be won as most of the FCF in our Base Case comes from ramping up already signed customers, along with some margin expansion from their AI/Machine learning initiatives. If the “network effect” we are predicting takes hold, we believe the Bull Case below is achievable.
Three more ideas are exclusively for paid subscribers.